Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

UCB Acquires Neurona Therapeutics for $1.15 Billion to Expand Epilepsy Portfolio – Regenerative Neural Cell Therapy NRTX-1001 Targets Drug-Refractory Epilepsy with Single-Dose GABA-Producing Cell Injection

Fineline Cube Apr 20, 2026
Company Deals

Pulnovo Medical Secures $100M+ Oversubscribed Financing Led by Medtronic – PADN System for Pulmonary Hypertension Attracts Global Investor Consortium

Fineline Cube Apr 20, 2026
Company Deals

SenseTime Raises $73.3 Million in Series A Financing for AI Healthcare Platform – Medical Agentic OS and World Model Capabilities Attract Raffles Healthcare, Lion Partners

Fineline Cube Apr 20, 2026
Company Deals

Mabwell Bioscience Raises $185 Million in Hong Kong IPO After Two Previous Failed Attempts – Oncology and Age-Related Disease Developer Secures HK$1.45 Billion Valuation

Fineline Cube Apr 20, 2026
Company Deals

Eli Lilly in Advanced Talks to Acquire Kelonia Therapeutics for Over $2 Billion – Strengthening CAR-T Cell Therapy Portfolio

Fineline Cube Apr 20, 2026
Policy / Regulatory

China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive

Fineline Cube Apr 21, 2026
Company Drug

FDA Grants Priority Review to Merck, Astellas, and Pfizer’s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer

Fineline Cube Apr 21, 2026
Company Drug

Novo Nordisk’s Oral Etavopivat Meets Primary Endpoints in Phase III HIBISCUS Trial for Sickle Cell Disease; Regulatory Filing Planned for H2 2026

Fineline Cube Apr 21, 2026
Company Drug

Hansoh Pharma’s Ibrexafungerp Approved for Vulvovaginal Candidiasis in China

Fineline Cube Apr 10, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced this week that it has received...

Company Drug

Hengrui Pharmaceuticals’ Ivarmacitinib Approved for Atopic Dermatitis

Fineline Cube Apr 10, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received additional indication approval...

Company Drug

Beijing StarMab’s SM2275 Receives FDA IND Approval for Dual-Target Cancer Therapy

Fineline Cube Apr 10, 2025

China-based Beijing StarMab BioMed Technology, Ltd. announced that it has received Investigational New Drug (IND)...

Company

GE Healthcare Appoints Jeannette Bankes as President and CEO of Patient Care Solutions

Fineline Cube Apr 10, 2025

GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced this week the appointment of Jeannette Bankes as...

Company Medical Device

Wantai Bio’s Tuberculosis Test Kit Joins UNOPS StopTB Procurement List

Fineline Cube Apr 10, 2025

China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) announced that its Tuberculosis infection...

Company Drug

B. Braun’s DUPLEX System Approved by FDA for Piperacillin and Tazobactam

Fineline Cube Apr 10, 2025

B. Braun Medical Inc., a US-based healthcare company, announced that the U.S. Food and Drug...

Company Drug

Sino Biopharma’s TQB3019 Gains NMPA Approval for Hematological Malignancies

Fineline Cube Apr 10, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that it has received clinical approval from the...

Company Medical Device

Peijia Medical’s YonFlow Stent Approved by China’s NMPA

Fineline Cube Apr 10, 2025

Peijia Medical Ltd (HKG: 9996) announced that it has received market approval from China’s National...

Company Medical Device

Gaush Meditech’s Corneal Confocal Microscope Approved in Jiangsu

Fineline Cube Apr 10, 2025

Suzhou-based Gaush Meditech Ltd (HKG: 2407) announced that it has received market approval from the...

Company Drug

Simcere Pharmaceutical Gains NMPA Approval for FGFR2b-Targeted ADC SIM0686

Fineline Cube Apr 10, 2025

China-based Simcere Pharmaceutical Group (HKG: 2096) announced that it has received clearance from the National...

Company Deals

Sinopep-Allsino Partners with Gulf Pharmaceutical for Semaglutide API Supply

Fineline Cube Apr 10, 2025

Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has signed...

Policy / Regulatory

U.S. Tariffs on Pharmaceuticals and Their Impact on China’s Medical Industry

Fineline Cube Apr 9, 2025

The U.S. administration’s decision to impose tariffs on pharmaceutical imports, effective April 9, has sent...

Company Drug

Sichuan Biokin Launches Phase III Trial for BL-B01D1 in Urothelial Carcinoma

Fineline Cube Apr 9, 2025

China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced the first patient enrollment in...

Company Drug

AbbVie’s Rinvoq Approved in EU for Giant Cell Arteritis

Fineline Cube Apr 9, 2025

US-based pharmaceutical giant AbbVie (NYSE: ABBV) announced that it has received marketing approval in the...

Company Drug

Bristol-Myers Squibb’s Opdivo/Yervoy Combo Approved for MSI-H Colorectal Cancer

Fineline Cube Apr 9, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) announced this week that the US Food and Drug Administration...

Company Drug

Yifan Pharma Secures NMPA Approval for Generic Sedapain

Fineline Cube Apr 9, 2025

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that it has received marketing approval...

Company Drug

Yunnan Baiyao’s INR102 Gains NMPA Clinical Trial Clearance for Prostate Cancer

Fineline Cube Apr 9, 2025

Yunnan Baiyao Group Co., Ltd (SHE: 000538), a traditional Chinese medicine (TCM) company based in...

Company Deals

Shanghai Kehua Bioengineering Launches Xi’an Medical Complex Project

Fineline Cube Apr 9, 2025

Shanghai Kehua Bioengineering Co., Ltd (SHE: 002022), a leading Chinese biotechnology company, has announced plans...

Company Deals

HuidaGene’s hfCas12Max Licensed to Vita Therapeutics for Neuromuscular Cell Therapy

Fineline Cube Apr 9, 2025

Shanghai-based genome medicines specialist HuidaGene Therapeutics has sublicensed its hfCas12Max platform to Vita Therapeutics, Inc.,...

Policy / Regulatory

NMPA Optimizes Drug Manufacturing License Process with Digital QR Codes

Fineline Cube Apr 9, 2025

The National Medical Products Administration (NMPA) has announced new measures to optimize the drug manufacturing...

Posts pagination

1 … 168 169 170 … 654

Recent updates

  • China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive
  • FDA Grants Priority Review to Merck, Astellas, and Pfizer’s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer
  • Boehringer Ingelheim Opens AI & Machine Learning Hub in London, Commits €150M to Accelerate Drug Discovery for High-Unmet-Need Diseases
  • Novo Nordisk’s Oral Etavopivat Meets Primary Endpoints in Phase III HIBISCUS Trial for Sickle Cell Disease; Regulatory Filing Planned for H2 2026
  • Akeso’s Cadonilimab Shows Promise in First-Line Pancreatic Cancer at AACR 2026; Dual PD-1/CTLA-4 Bispecific Gains Guideline Endorsements Across Seven Cancers
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive

Company Drug

FDA Grants Priority Review to Merck, Astellas, and Pfizer’s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer

Company Digital

Boehringer Ingelheim Opens AI & Machine Learning Hub in London, Commits €150M to Accelerate Drug Discovery for High-Unmet-Need Diseases

Company Drug

Novo Nordisk’s Oral Etavopivat Meets Primary Endpoints in Phase III HIBISCUS Trial for Sickle Cell Disease; Regulatory Filing Planned for H2 2026

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.